This trial studies the side effects and best dose of activated T cells armed with GD2 bispecific antibody and how well they work in treating patients with neurblastoma, osteosarcoma, and other GD2+ solid tumors.

Project Title: Activated T-Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcomas
Researcher: Maxim Yankelevich, MD
Institution: Barbara Ann Karmanos Cancer Institute
Study Type: Phase 1 Clinical Trial
Status: Ongoing

This trial studies the side effects and best dose of activated T-cells armed with GD2 bispecific antibody and how well they work in treating patients with neuroblastoma, osteosarcoma, and other GD2+ solid tumors. This study will provide new information on whether infusions of these activated T-cells will not only kill the tumor, but also “vaccinate” the patients against their own cancer resulting in significant improvement in survival for patients with relapsed GD2-positive tumors.

To learn more about this trial, visit clinicaltrials.gov.

Charity Partners: Fishin’ For The Cure